Drug Profile
Research programme: macrocyclic peptide therapeutics - Circle Pharma
Alternative Names: Cancer therapeutics - Circle Pharma; CyclinA/Cdk2-targeting molecules - Circle Pharma; MCL1-targeting molecules - Circle PharmaLatest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Circle Pharma
- Developer Circle Pharma; Pfizer
- Class Antineoplastics; Macrocyclic compounds; Peptides
- Mechanism of Action CXCR7 protein modulators; Cyclin inhibitors; Cyclin-dependent kinase 2 modulators; Intracellular signalling peptide and protein inhibitors; MCL1 protein modulators; Protein-protein interaction inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer